(NASDAQ: CRMD) Cormedix's forecast annual revenue growth rate of 4.94% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.87%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.08%.
Cormedix's revenue in 2026 is $311,709,000.On average, 9 Wall Street analysts forecast CRMD's revenue for 2026 to be $24,852,653,684, with the lowest CRMD revenue forecast at $22,814,734,501, and the highest CRMD revenue forecast at $26,896,896,899. On average, 9 Wall Street analysts forecast CRMD's revenue for 2027 to be $23,126,983,561, with the lowest CRMD revenue forecast at $18,523,088,556, and the highest CRMD revenue forecast at $26,636,030,595.
In 2028, CRMD is forecast to generate $28,475,533,287 in revenue, with the lowest revenue forecast at $26,254,217,187 and the highest revenue forecast at $31,610,671,953.